Version 1
: Received: 2 November 2023 / Approved: 3 November 2023 / Online: 3 November 2023 (07:57:10 CET)
How to cite:
Wang, J.; Xu, B.; Jia, X.; He, Y.; Jia, B.; Li, J.; Xu, M. Predictive Value of Der P 2-Specific IgE for Subcutaneous Immunotherapy in Children With Allergic Rhinitis. Preprints2023, 2023110224. https://doi.org/10.20944/preprints202311.0224.v1
Wang, J.; Xu, B.; Jia, X.; He, Y.; Jia, B.; Li, J.; Xu, M. Predictive Value of Der P 2-Specific IgE for Subcutaneous Immunotherapy in Children With Allergic Rhinitis. Preprints 2023, 2023110224. https://doi.org/10.20944/preprints202311.0224.v1
Wang, J.; Xu, B.; Jia, X.; He, Y.; Jia, B.; Li, J.; Xu, M. Predictive Value of Der P 2-Specific IgE for Subcutaneous Immunotherapy in Children With Allergic Rhinitis. Preprints2023, 2023110224. https://doi.org/10.20944/preprints202311.0224.v1
APA Style
Wang, J., Xu, B., Jia, X., He, Y., Jia, B., Li, J., & Xu, M. (2023). Predictive Value of Der P 2-Specific IgE for Subcutaneous Immunotherapy in Children With Allergic Rhinitis. Preprints. https://doi.org/10.20944/preprints202311.0224.v1
Chicago/Turabian Style
Wang, J., Junyuan Li and Ming Xu. 2023 "Predictive Value of Der P 2-Specific IgE for Subcutaneous Immunotherapy in Children With Allergic Rhinitis" Preprints. https://doi.org/10.20944/preprints202311.0224.v1
Abstract
Dermatophagoides pteronyssinus (Der p) subcutaneous immunotherapy (SCIT) has demonstrated efficacy in clinical trials of childhood allergic rhinitis (AR). Currently, there is a lack of some generally accepted biomarkers that may predict the clinical response to SCIT to eventually achieve personalized therapy. In this study, 28 children with AR received Der p SCIT for 26-30 months at baseline, and four efficacy endpoints, serum interleukin (IL)-5, periostin, Der p-specific IgE (sIgE), and Der p sIgG4, were measured by ELSIA. Clinical symptoms and characteristics were assessed by questionnaires, and the associations among periostin, Der p 2 sIgE and clinical efficacy were analyzed. The results showed that SCIT demonstrated a significant reduction in Der p 1 sIgE (P < 0.05) and Der p 2 sIgE (P < 0.01), an increase in Der p sIgG4 (P < 0.001) and an improvement in clinical efficacy at the fourth efficacy endpoint compared with that at baseline. A positive linear correlation was found in serum periostin and Der p sIgE (Pearson correlation=0.8868, P=0.045), Der p sIgG4 (Pearson correlation=-0.9025, P=0.036), and clinical efficacy. Importantly, the concentration of serum Der p 2 sIgE showed a positive linear correlation with clinical efficacy and serum periostin (Pearson correlation=0.9581, P=0.010). These results suggest that SCIT can result in reduced type 2 cytokines and Der p sIgE and has long-term efficacy in children with AR. Der p 2 sIgE has a positive linear correlation with clinical efficiency and serum periostin and may be a useful biomarker for the prediction of SCIT.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
